Skip to content

In Vivo Investigation on Bio-markers of Perimenopausal Panic Disorder and Catgut Embedding Acupoints Mechanism

In Vivo Investigation on Brain Neural Activation and Glutamate and GABA of Perimenopausal Panic Disorder Treated by Catgut Embedding Acupoints

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009724
Enrollment
Unknown
Registered
2016-11-03
Start date
2016-11-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopausal Panic Disorder

Interventions

Treatment Group:Acupoint Catgut Embedding Therapy
Drug Group:Alprazolam

Sponsors

Affiliated Bao'An Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
41 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnosis of panic disorder set by American Psychiatric Association(DSM-V): At some time during the disturbance, one or more panic attacks occurred that were unexpected and were ROt triggered by situations in which the person was the focus of attention; Four attacks have occurred during a 4-week period, or one or more attacks have been followed by a period of at least 1 month of persistent fear of having another attack. At least four of the following symptoms occurred during at least one of the attacks: Shortness of breath (dyspnea) or a smothering sensation; Dizziness, unsteady feeling, or fainting; Palpitations or accelerated heart rate (tachycardia); Trembling or shaking; Sweating; Choking; Nausea or abdominal distress; Depersonalization (the feeling that one's body is unreal) or derealization (the feeling that reality is altered); Numbness or tingling sensations (paresthesia); Flushes (hot flashes) or chills; Chest pain or discomfort; Fear of dying; Fear of going crazy or of doing something uncontrolled; In one of the attacks, at least four of the symptoms developed suddenly and increased in intensity within 10 minutes of the beginning of the first symptom noticed in the attack. No organic factor (eg, amphetamine or caffeine intoxication, hyperthyroidism} started or maintained the disturbance; 2. Female, aged 41-60 yrs old, right handed,9 yrs of education or above; 3. HAMA score =14 points; 4. Signning the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Associated co-morbidity, such as phobia, depression, or panic attack secondary to body disorder; 2. Associated severe heart, liver, kidney diseases, or severe disorders of other systems; or malignant tumor. 3. Panic attack secondary to body diseases, e.g.,epilepsy, heart attack,pheochromocytoma,hyperthyroid or spontaneous hypoglycemia; 4. Those taken antipsychotic drugs,antidepressive drug, sex horme drug, or cognitve behavior therapy within 2 weeks; 5. Contraindicated to MR scanning: Aneurysm clip,embedding nerve stimulator, cardiac pacemaker, automatic defibrillator,cochlea electrode embedment, or visual body sensation; 6. Pregnant or lactation women; 7. Alcoholic and drug abuse, or addiction within 1 year.

Design outcomes

Primary

MeasureTime frame
Frequency of Panic Attach;Panic Disorder Severity;Brain Functional Activation;

Secondary

MeasureTime frame
Panic Associated Symptom Scaling ;Anxiety Symptom Evaluation;Kupperman Scale;

Countries

China

Contacts

Public ContactGuizhen Chen

Affiliated Bao'an Hospital of TCM, Guangzhou University of Chinese Medicine

cgzhen2000@163.com+86 13510173825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026